A 996 bp Aspergihs nidulans cDNA encoding the ASPNDl immunodominant antigen was cloned and expressed in Escherichia coli as a fusion protein with the enzyme glutathione S-transferase (GST) from Schistosoma japonicum. The GST-ASPND1 fusion protein was purified from isolated bacterial inclusion bodies by preparative SDS-PAGE. After cleavage with thrombin, the ASPNDl recombinant antigen (ASPNDlr) and the GST protein were separated by SDS-PAGE and immunoblotted with a number of different human sera. The sera from 22 (88%) of 25 patients with an aspergilloma recognized the ASPNDlr recombinant antigen on immunoblots. Forty-nine normal human sera and 14 sera from patients with other infections were unreactive. The ASPNDlr expressed in E. coli could therefore be used, in combination with previously reported recombinant antigens, as a standardized antigen for serological and clinical diagnosis of Aspergillus-associated diseases.
INTRODUCTION
The aspergilloses are a complex array of diseases ranging from pulmonary aspergilloma to invasive aspergillosis, and including various allergic reactions (Kwon-Chung & Bennett, 1992) . Different species of the genus Aspergillus, a ubiquitous mould common in soil and plant debris, are the aetiological agents of these infections, whose diagnosis depends on clinical and immunological findings. Specific circulating antibodies against Aspergillus fumigatus antigens have been recognized in most of these diseases (Kurup & Kumar, 1991) . However, for many years the lack of standardized antigens has thrown doubt on the reliability of antibody assays (Kwon- antigens have been purified to homogeneity from A. fumigatus water-soluble extracts. Currently, the best way to circumvent these problems relies on the use of purified homogeneous recombinant antigens and allergens of known biological activity. The Asp f Z ribotoxin (Moser et al., 1992) , the Asp f ZI allergen (Banerjee et al., 1996) , and the heat-shock protein (HSP-1) (Kumar et al., 1993) from A. fumigatus have been obtained as recombinant antigens. All these antigens have been shown to be consistently reactive with sera from patients with different forms of aspergillosis but not with sera from control or healthy individuals (Moser et al., 1994; Banerjee et al., 1996; Lopez-Medrano et al., 1996; Hamilton et al., 1995) . 8~ Bennett, 1992) . Owing to the intrinsic problems associated with the preparation of antigenic mixtures, many attempts have been made to standardize Although Aspergillus nidulans is not the most frequently isolated species from aspergillosis patients, it does constitute an alternative model to enable various aspects extracts Or to Purify defined antigens* Among others, the CAT' (the subunit of a catalase) (LOP' ' -of the pathogenesis and immunodiagnosis of Aspergillus infections to be studied. In support of this assumption, Medrano et 1995b) specific humoral response in different forms of As-
The EMBL accession number for the sequence reported in this paper is pergillus infections (Calera et al.7 1997) . Antigens
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belonging to this family, mainly p40 and p37 (Lopez- et al., 1996) and Asp f ZZ (Banerjee et al., 1996) from A. fumigatus and ASPND1 from A. nidulans (Calera et al., 1994) , have been shown to be specific markers for clinical infections caused by Aspergillus, regardless of the species originally involved. Asp f ZZ antigen has been produced in recombinant form (Banerjee et al., 1996) , thus avoiding the problems of the batch-to-batch variability associated with its production from the original fungal host. We have recently cloned and characterized the A. nidulans gene coding ASPND1
and reported its similarity to A. fumigatus Asp f ZZ allergen (Calera et al., 1997) . In this work, we describe the overexpression in Escherichia coli of an ASPND1 cDNA and evaluate the ability of this recombinant antigen (ASPNDlr) to be specifically recognized by immune human sera.
METHODS
Organisms and growth conditions. Aspergillus nidulans GlO59wt (adFl7, pabaA2, yA2) was obtained from A. J.
Clutterbuck (University of Glasgow, Scotland) and grown as previously described (Calera et al., 1997) . The following E. coli strains were used : strain Y 1090 was used for propagation of bacteriophage i g t l l ; all plasmid subcloning and overexpression experiments were performed in strain DHSa ; strain MV1190 was used to obtain single-strand DNA for sequencing; and strain Y1089 was used to obtain lysogen. All bacterial strains were grown at 37 "C in Luria broth medium (Sambrook et al., 1989) . SDSPAGE. Electrophoreses were carried out on a Protean I1 or Mini-Protean apparatus (Bio-Rad) on isotropic 14 '/o or 16 '/o (w/v) acrylamide slab gels (8 x 6 x 0.1 cm) using the discontinuous buffer system of Laemmli (1970) . Molecular mass protein standards were normal or prestained Bio-Rad lowmolecular-mass markers. Proteins in gels were detected by a sensitive silver stain (Morrisey, 1981) or by staining for 30 min with 0.5% Coomassie brilliant blue R-250 in acetic acid/ 2-propanol/water (1 : 3 : 6) and destaining in acetic acid/ methanol/water (10: 5 : 85).
Electrophoretic blotting procedures and immunological detection of proteins. Proteins from extracts were first subjected to SDS-PAGE as described above and transferred to nitrocellulose sheets (0.45 pm; Schleicher & Schuell) in a TransBlot Cell (Bio-Rad) as previously described (Calera et al., 1994 (Sambrook et al., 1989) .
Positive plaques were identified and recovered from agar plugs. The positive phages were purified following the glycerol step gradient method as decribed by Sambrook et al. (1989) . DNA inserts were excised with EcoRI and subcloned into pBluescript SK( + ) and KS( + ) by standard procedures (Sambrook et al., 1989) .
Preparation of bacteriophage Agtl 1 lysogens. Lysates containing fusion proteins encoded by phage i g t l l lysogens were prepared as described by Huynh et al. (1985) DNA preparation and analysis. Normal DNA manipulations were carried out as indicated by Sambrook et al. (1989) . Plasmid DNA was extracted from E. coli DH5a according to the instructions of the Wizard DNA Purification System (Promega). Restriction enzymes and T 4 DNA ligase were obtained from Boehringer and used under the recommended conditions. Restriction fragments of genomic DNA carrying the aspndl gene were subcloned into pBluescript SK( + ) and KS( + ) vectors (Stratagene). Single-stranded DNAs from overlapping deletions generated according to the doublestranded nested deletion kit (Pharmacia) were sequenced by the dideoxy chain-termination method (Sanger et al., 1977) using the Pharmacia T7 polymerase sequencing kit and following the supplier's instructions, with 35S-labelled dATP (Amersham) as labelled dNTP.
Construction of expression vector pGSTag-cDNAaspndl. The cDNA encoding mature ASPND1 was purified using the double Gene Clean procedure (BiolOl), digested with NcoI and ligated into plasmid pGSTag (Ron & Dressler, 1992) by standard protocols. Vector pGSTag-cDNAaspndl was used to transform competent E. coli DH5a and transformants were selected on LB plates with ampicillin (100 pg ml-l) according to standard protocols (Sambrook et al., 1989) . Correct transformants were isolated after analysis of plasmid DNA from randomly selected transformants and digested with BamHI (within the pGSTag polylinker) and PvuII (within the cDNA 5' end).
Production and purification of glutathione S-transferase (GSTkASPNDl r. A 20 ml sample of an overnight culture of the A. nidulans ASPNDlr antigen correct transformant E. coli DH5a grown at 37°C in LB containing 0.1 mg ampicillin ml-l was used as preinoculum for 180 ml of fresh LB containing 0.1 mg ampicillin ml-'. After 2 h growth at 37 "C in a shaking incubator, IPTG was added at a final concentration of 0.1 mM to induce GST-ASPNDlr synthesis. Cells were pelleted and lysed after 4 h IPTG induction, according to the method described by Marston (1987) . The fusion protein was found to accumulate as inclusion bodies, which were purified by centrifugation at 4000g for 15 min at 4 "C. Purified and washed inclusion bodies were resuspended in SDS gel loading buffer and GST-ASPNDlr was purified to homogeneity by preparative electrophoresis.
Preparative electrophoresis. Recombinant ASPND 1 was purified bv preparative electrophoresis in a Prep Cell apparatus (model 491, Bio-Rad) according to the manufacturer's instructions. An isotropic 10 O/O (w/v) polyacrylamide cylindrical gel (1 10 mm long, 37 mm diameter) was prepared using the discontinuous buffer of Laemmli (1970) . The sample was run at 10 W constant power for 14 h at room temperature. To prevent overheating, buffer was recirculated through the cooling core of the apparatus. Elution of the protein was monitored by UV absorbance (Waters 490 programmable multiwavelength detector, Millipore) and 1.5 ml fractions were collected (Frac-100 collector, Pharmacia). All fractions were subjected to SDS-PAGE and those containing the purified protein were mixed together and stored at -70 "C.
Thrombin digestion of the fusion protein (GST-ASPND1 r).
The GST-ASPNDlr protein purified by preparative electrophoresis was in soluble form at a concentration of 0.1 mg ml-l in 25 mM Tris buffer, pH 8. Densitometric quantification of the blots. Densitometry was done with a Bioimage system using the Whole Band Analyzer software (Millipore). Integrated optical density (IOD) arbitrary units were used to express the results.
RESULTS

Molecular cloning and sequencing of cDNA for ASPNDl immunodominant antigen from A. nidulans
Screening of 2-2 x lo4 recombinant Agtll plaques of the cDNL4 library with affinity-purified antibodies revealed six strongly hybridizing clones designated Fl-F6. Lysogens were prepared as described in Methods to ascertain if all the clones encoded the ASPND1 antigen and to determine which ones contained longer encoding cDNAs. T o determine whether expression of the fusion protein was under control of the lac2 promoter, lysates of the recombinant lysogens were examined by immunoblotting after heat induction at 45 "C followed by growth at 37 "C for 60 min in the absence or presence of 1 mM IPTG (Fig. 1) . A lysogen expressing only the pgalactosidase was used as negative control. The six selected clones expressed the correct epitope, as demonstrated by their reactivity with the purified monospecific (-) or induced (+) with 1 mM IPTG. Affinity-purified anti-ASPND1 antibody was used a t a dilution of 1 : 1000. Experimental details are described in Methods.
antibody. Phage DNA from clones F3 and F5 (producing larger fusion proteins) and from clone F4 (producing the smallest fusion protein) was isolated. Digestion of these DNAs with EcoRI yielded three unique fragments of about 1.0, 0-95 and 0.5 kbp respectively. The three fragments were subcloned into pBluescript SK( + ) and KS( + ) in the EcoRI site and sequenced. The exact size of each fragment was 996 bp for clone F3, 878 bp for clone F5, and 429 bp for clone F4. All three clones came from the same mRNA (as determined by comparison of their nucleotide sequences) and contained the 3' poly(A) tail. Differences in size were due to the presence of different 5' ends, probably caused by arrest of the reverse transcriptase at different positions in the mRNA template. The nucleotide sequence of the largest clone (F3) has been deposited in the EMBL database (accession no.
280229). It displays an open reading frame of 789 bp
preceded by 2 bp of 5' sequence and followed by 205 bp of 3' untranslated sequence, terminating with a putative polyadenylation signal and a poly(A) tail. The absence of a consensus translational start signal (ATG) indicated that the F3 cDNA was not a complete copy of the ASPNDl mRNA. Nucleotide sequence analysis of this clone confirmed that it encoded ASPND1 antigen since the first 14 residues of the predicted amino acid sequence of the translation product coincided exactly with the corresponding residues of the previously determined Nterminal amino acid sequence of purified ASPND 1 (Calera et al., 1997) .
Comparison of the cDNA and genomic sequences (Calera et al., 1997) showed that the missing region in clone F3 would correspond to a signal peptide of 16 amino acids preceding the mature product.
Expression of ASPNDl antigen in Em coli
Plasmid vectors have been constructed that express antigens as fusion proteins with the enzyme GST from Schistosoma japonicum, thereby enabling affinity-purification under non-denaturing conditions (Johnson et al., 1989) . The fusion protein GST-ASPNDlr was prepared by introducing the NcoI-digested insert from clone F3 into the NcoI site of vector pGSTag (Fig. 2) . Induction with IPTG at 37 "C for various periods of time followed by SDS-PAGE of the total protein revealed a major IPTG-induced band at 63.7 kDa (Fig. 3 ). This band is 5.2 kDa larger than the estimated size deduced from the sequence data. This fact was also noticed with the original ASPND1 antigen and is due to the abnormal electrophoretic mobility of ASPND1 in SDS-PAGE (Calera et al., 1997) . The soluble supernatant from the lysate of induced cells showed very low levels of reactivity with the specific antibody. The fusion protein accumulates as inclusion bodies, which are easily visible by light microscopy, thus preventing the possibility of affinity purification even after its solubilization with Sarkosyl (Frankel et al., 1991 ; Frangioni & Neel, 1993) .
Inclusion bodies were then purified as described in Methods (Fig. 3, lane IB) and the fusion protein was isolated by preparative SDS-PAGE (Fig. 3, lane P) . The yield of purified GST-ASPNDlr was around 90-120 mg 1-l. Since the GST protein is a very strong antigenic molecule (it is used for the immunodiagnosis of some forms of parasitosis such as schistosomiasis ; Lin et al., 1993) , we decided to separate the ASPND1 recombinant protein (ASPNDlr) from the GST moiety to prevent the appearance of false-positive reactions. Taking advantage of the existence in the pGSTag vector of a target sequence for cleavage with thrombin, we digested the fusion protein with this protease to obtain an ASPND1 recombinant antigen (Fig. 4) . ASPNDlr contained 34 extra N-terminal amino acids corresponding to the coding region determined by the DNA fragment containing the different cloning sites of the pGSTag vector between the site of thrombin cleavage and the NcoI restriction site (Fig. 2) . 
A. nidulans ASPNDlr antigen
Specific recognition of ASPNDI r by immune human sera
Purified GST-ASPND l r fusion protein was digested with thrombin and the cleaved polypeptides (GST and ASPNDlr) were separated by SDS-PAGE (Fig. 4) and transferred to Immobilon. Several parallel blots were cut into numerous strips, each of which was incubated with a different human serum sample at a dilution of 1 : 200. Fig. 5 shows the results obtained after developing with peroxidase reagents. Of the 25 serum samples from patients with confirmed aspergilloma, 22 (88 YO) were reactive with ASPNDlr, with the appearance of a single band in the immunoblot. Reaction intensities varied among patients. None of the 49 serum samples from healthy individuals showed reactivity (data not shown). Of 15 serum samples from patients with different clinical situations, only one, from a patient with positive rheumatoid factor, was clearly reactive to ASPND lr. The remaining 14 control sera from miscellaneous infections showed negligible or no reactivity (data not shown). Densitometric quantification of the blots is shown in Fig. 6 . An IOD of 0.04 (Fig. 6, dashed line) corresponds to the mean (0.01) plus four standard deviations (4 x 0.007) calculated for the 64 control serum samples from 49 blood bank donors and 15 patients with diseases unrelated to Aspergillus. Of the 25 serum samples from patients with aspergilloma, 22 gave IOD values equal to or greater than 0-04 (Fig. 6, left panel) , whereas only one of 64 negative controls gave a value greater than 0.04 (Fig. 6, right panel) . In view of these data, the assay was considered positive if the detected ASPNDlr band had an IOD equal to or greater than 0.04 and negative if the IOD was lower than 0.04. 
DISCUSSION
We have obtained an immunodominant A. nidulans antigen in recombinant form and have analysed its ability to react with immune human sera. The ASPNDlr antigen was consistently recognized by serum samples from aspergilloma patients and proved to be a marker specific for Aspergillus infections in the sense that sera from healthy blood donors and patients with infections other than aspergilloses did not recognize it significantly. When compared to the original complex antigen mixture, the assay proved to be more sensitive (88% with ASPNDlr vs 75% with the complex mixture; LopezMedrano et al., 1996; Calera et al., 1997) . This higher sensitivity is probably due to the fact that in SDS-PAGE ASPNDlr gives a single narrow band, with a higher protein concentration, instead of the broad zone observed in the case of total extracts. The specificity of the assay was the same when either ASPNDlr or the total extract was used. This result was predictable considering that only the reactivity of the ASPND1 zone with different serum samples was taken into account for positivity when total extracts were used.
Aspergilloma patients are known to demonstrate numerous Aspergillus-specific precipitins and therefore provide a ' filter ' for identifying clinically relevant antigens. Based on this assumption, we had previously identified certain immunodominant antigens from A. fumigatus after monitoring their consistent reactivity with a high proportion of adequately documented sera from aspergilloma patients (Lopez-Medrano et al., 1995a) . One of these antigens -p90 or CATl -proved to be a relevant antigen as a specific marker for the immunodiagnosis of pulmonary aspergilloma (LopezMedrano et al., 1996) and was shown to possess catalase activity (Lopez-Medrano et al., 1995b) . Using basically the same collection of aspergilloma sera, we also established the clinical relevance of the A. nidulans antigen designated ASPND1 (Calera et al., 1994 (Calera et al., , 1997 -now expressed in recombinant form as ASPNDlrand demonstrated its similarity to the A. fumigatus A s p f I1 allergen (Calera et al., 1997) . The fact that the same array of serum samples scored positive for CAT1, ASPND1 and ASPNDlr antigens reinforces their value as potential markers for Aspergillus infections. An adequate number of sera from invasive aspergillosis and allergic bronchopulmonary aspergillosis ( ABPA) patients should be tested in the future to evaluate the usefulness of ASPNDlr as a marker for these types of d' isease.
Healthy individuals often show a certain degree of recognition to Aspergillus antigens (Hearn, 1988) . Accordingly, the lack of reactivity to ASPNDlr of the 49 serum samples from blood bank donors is very significant. The serum samples from three out of 25 (12 % )
patients with confirmed Aspergillus infections were not reactive to ASPNDlr. This may be due to variations in the immunological responses of different individuals and would represent a low percentage of false-negative reactions. These would be negligible if this recombinant antigen were used for clinical purposes in combination with other previously reported antigens.
The frequently observed non-specific reactivity of GST protein with different types of serum samples reinforces the need to excise the GST-ASPNDlr fusion protein before the immunoblot step to avoid false-positive reactions.
Several perfectly characterized antigens have been shown to be relevant for the immunodiagnosis of Aspergillus infections and their recombinant counterparts have been obtained: HSP-1 (Kumar et al., 1993) A s p f ZZ (Banerjee et al., 1996) , rAsp f I/a (Moser et al., 1992 (Moser et al., , 1994 al., 1995b) and the superoxide dismutase antigen , have been purified to homogeneity and will probably be produced as recombinant proteins in the near future. All these antigens should be evaluated together, or in appropriate combinations, for the manufacture of defined reagents for a consistent diagnosis of the different forms of aspergillosis.
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